APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Basal Cell Nevus Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Basal Cell Nevus Syndrome Drug Industry Research Report 2026

Report ID 173969270519 December 2025123 pages

Choose your research edition.

Industry ResearchBasal Cell Nevus Syndrome Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Basal Cell Nevus Syndrome Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Basal Cell Nevus Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Basal Cell Nevus Syndrome Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Basal Cell Nevus Syndrome Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Basal Cell Nevus Syndrome Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Basal Cell Nevus Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Basal Cell Nevus Syndrome Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Basal Cell Nevus Syndrome Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Basal Cell Nevus Syndrome Drug include Transgene SA, PellePharm Inc, Mayne Pharma Group Ltd, Galderma SA and Adgero Biopharmaceuticals Holdings Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Basal Cell Nevus Syndrome Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Basal Cell Nevus Syndrome Drug Market by Company

Transgene SA

PellePharm Inc

Mayne Pharma Group Ltd

Galderma SA

Adgero Biopharmaceuticals Holdings Inc

Basal Cell Nevus Syndrome Drug Segment by Type

Itraconazole

Patidegib Hydrochloride

Trifarotene

TG-1042

REM-001

Others

Basal Cell Nevus Syndrome Drug Segment by Application

Clinic

Hospital

Others

Basal Cell Nevus Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Basal Cell Nevus Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Basal Cell Nevus Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Basal Cell Nevus Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Basal Cell Nevus Syndrome Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Basal Cell Nevus Syndrome Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Basal Cell Nevus Syndrome Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Basal Cell Nevus Syndrome Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Basal Cell Nevus Syndrome Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Basal Cell Nevus Syndrome Drug Revenue of Manufacturers (2021-2026) Table 9. Global Basal Cell Nevus Syndrome Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Basal Cell Nevus Syndrome Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Basal Cell Nevus Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Basal Cell Nevus Syndrome Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Basal Cell Nevus Syndrome Drug, Product Type & Application Table 14. Global Basal Cell Nevus Syndrome Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Basal Cell Nevus Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Transgene SA Company Information Table 19. Transgene SA Business Overview Table 20. Transgene SA Basal Cell Nevus Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Transgene SA Basal Cell Nevus Syndrome Drug Product Portfolio Table 22. Transgene SA Recent Developments Table 23. PellePharm Inc Company Information Table 24. PellePharm Inc Business Overview Table 25. PellePharm Inc Basal Cell Nevus Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. PellePharm Inc Basal Cell Nevus Syndrome Drug Product Portfolio Table 27. PellePharm Inc Recent Developments Table 28. Mayne Pharma Group Ltd Company Information Table 29. Mayne Pharma Group Ltd Business Overview Table 30. Mayne Pharma Group Ltd Basal Cell Nevus Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Mayne Pharma Group Ltd Basal Cell Nevus Syndrome Drug Product Portfolio Table 32. Mayne Pharma Group Ltd Recent Developments Table 33. Galderma SA Company Information Table 34. Galderma SA Business Overview Table 35. Galderma SA Basal Cell Nevus Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Galderma SA Basal Cell Nevus Syndrome Drug Product Portfolio Table 37. Galderma SA Recent Developments Table 38. Adgero Biopharmaceuticals Holdings Inc Company Information Table 39. Adgero Biopharmaceuticals Holdings Inc Business Overview Table 40. Adgero Biopharmaceuticals Holdings Inc Basal Cell Nevus Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Adgero Biopharmaceuticals Holdings Inc Basal Cell Nevus Syndrome Drug Product Portfolio Table 42. Adgero Biopharmaceuticals Holdings Inc Recent Developments Table 43. Global Basal Cell Nevus Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Basal Cell Nevus Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Region (2021-2026) Table 46. Global Basal Cell Nevus Syndrome Drug Sales by Region (2027-2032) & (K Units) Table 47. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Region (2027-2032) Table 48. Global Basal Cell Nevus Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 49. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Region (2021-2026) Table 50. Global Basal Cell Nevus Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 51. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Region (2027-2032) Table 52. North America Basal Cell Nevus Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 53. North America Basal Cell Nevus Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 54. North America Basal Cell Nevus Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 55. North America Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 56. North America Basal Cell Nevus Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 57. Europe Basal Cell Nevus Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Europe Basal Cell Nevus Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 59. Europe Basal Cell Nevus Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 60. Europe Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 61. Europe Basal Cell Nevus Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 62. Asia Pacific Basal Cell Nevus Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Asia Pacific Basal Cell Nevus Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 64. Asia Pacific Basal Cell Nevus Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 65. Asia Pacific Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 66. Asia Pacific Basal Cell Nevus Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 67. South America Basal Cell Nevus Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. South America Basal Cell Nevus Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 69. South America Basal Cell Nevus Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 70. South America Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 71. South America Basal Cell Nevus Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 72. Middle East and Africa Basal Cell Nevus Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Middle East and Africa Basal Cell Nevus Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 74. Middle East and Africa Basal Cell Nevus Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 75. Middle East and Africa Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 76. Middle East and Africa Basal Cell Nevus Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 77. Global Basal Cell Nevus Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 78. Global Basal Cell Nevus Syndrome Drug Sales by Type (2027-2032) & (K Units) Table 79. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Type (2021-2026) Table 80. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Type (2027-2032) Table 81. Global Basal Cell Nevus Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 82. Global Basal Cell Nevus Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 83. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Type (2021-2026) Table 84. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Type (2027-2032) Table 85. Global Basal Cell Nevus Syndrome Drug Price by Type (2021-2026) & (US$/Unit) Table 86. Global Basal Cell Nevus Syndrome Drug Price by Type (2027-2032) & (US$/Unit) Table 87. Global Basal Cell Nevus Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 88. Global Basal Cell Nevus Syndrome Drug Sales by Application (2027-2032) & (K Units) Table 89. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Application (2021-2026) Table 90. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Application (2027-2032) Table 91. Global Basal Cell Nevus Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 92. Global Basal Cell Nevus Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 93. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Application (2021-2026) Table 94. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Application (2027-2032) Table 95. Global Basal Cell Nevus Syndrome Drug Price by Application (2021-2026) & (US$/Unit) Table 96. Global Basal Cell Nevus Syndrome Drug Price by Application (2027-2032) & (US$/Unit) Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Basal Cell Nevus Syndrome Drug Distributors List Table 100. Basal Cell Nevus Syndrome Drug Customers List Table 101. Basal Cell Nevus Syndrome Drug Industry Trends Table 102. Basal Cell Nevus Syndrome Drug Industry Drivers Table 103. Basal Cell Nevus Syndrome Drug Industry Restraints Table 104. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Basal Cell Nevus Syndrome Drug Product Image Figure 5. Global Basal Cell Nevus Syndrome Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Basal Cell Nevus Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Basal Cell Nevus Syndrome Drug Sales (2021-2032) & (K Units) Figure 8. Global Basal Cell Nevus Syndrome Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Itraconazole Product Image Figure 10. Patidegib Hydrochloride Product Image Figure 11. Trifarotene Product Image Figure 12. TG-1042 Product Image Figure 13. REM-001 Product Image Figure 14. Others Product Image Figure 15. Clinic Product Image Figure 16. Hospital Product Image Figure 17. Others Product Image Figure 18. Global Basal Cell Nevus Syndrome Drug Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Basal Cell Nevus Syndrome Drug, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Basal Cell Nevus Syndrome Drug Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Basal Cell Nevus Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Basal Cell Nevus Syndrome Drug Sales by Region in 2025 Figure 24. Global Basal Cell Nevus Syndrome Drug Revenue by Region in 2025 Figure 25. North America Basal Cell Nevus Syndrome Drug Market Size by Country in 2025 Figure 26. North America Basal Cell Nevus Syndrome Drug Sales Market Share by Country (2021-2032) Figure 27. North America Basal Cell Nevus Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 28. United States Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Basal Cell Nevus Syndrome Drug Market Size by Country in 2025 Figure 31. Europe Basal Cell Nevus Syndrome Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Basal Cell Nevus Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Basal Cell Nevus Syndrome Drug Market Size by Country in 2025 Figure 39. Asia Pacific Basal Cell Nevus Syndrome Drug Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Basal Cell Nevus Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 41. China Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Basal Cell Nevus Syndrome Drug Market Size by Country in 2025 Figure 50. South America Basal Cell Nevus Syndrome Drug Sales Market Share by Country (2021-2032) Figure 51. South America Basal Cell Nevus Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 52. Mexico Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Middle East and Africa Basal Cell Nevus Syndrome Drug Market Size by Country in 2025 Figure 56. Middle East and Africa Basal Cell Nevus Syndrome Drug Sales Market Share by Country (2021-2032) Figure 57. Middle East and Africa Basal Cell Nevus Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 58. Turkey Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. UAE Basal Cell Nevus Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Type (2021-2032) Figure 62. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 63. Global Basal Cell Nevus Syndrome Drug Price (US$/Unit) by Type (2021-2032) Figure 64. Global Basal Cell Nevus Syndrome Drug Sales Market Share by Application (2021-2032) Figure 65. Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 66. Global Basal Cell Nevus Syndrome Drug Price (US$/Unit) by Application (2021-2032) Figure 67. Basal Cell Nevus Syndrome Drug Value Chain Figure 68. Basal Cell Nevus Syndrome Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Basal Cell Nevus Syndrome Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Itraconazole
  • Patidegib Hydrochloride
  • Trifarotene
  • TG-1042
  • REM-001
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Transgene SA
  • PellePharm Inc
  • Mayne Pharma Group Ltd
  • Galderma SA
  • Adgero Biopharmaceuticals Holdings Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Basal Cell Nevus Syndrome Drug Market Size (2021-2032)
  4. 2.2.2 Global Basal Cell Nevus Syndrome Drug Sales (2021-2032)
  5. 2.2.3 Global Basal Cell Nevus Syndrome Drug Market Average Price (2021-2032)
  6. 2.3 Basal Cell Nevus Syndrome Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Itraconazole
  9. 2.3.3 Patidegib Hydrochloride
  10. 2.3.4 Trifarotene
  11. 2.3.5 TG-1042
  12. 2.3.6 REM-001
  13. 2.3.7 Others
  14. 2.4 Basal Cell Nevus Syndrome Drug by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Clinic
  17. 2.4.3 Hospital
  18. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Basal Cell Nevus Syndrome Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Basal Cell Nevus Syndrome Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Basal Cell Nevus Syndrome Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Basal Cell Nevus Syndrome Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Basal Cell Nevus Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Basal Cell Nevus Syndrome Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Basal Cell Nevus Syndrome Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Basal Cell Nevus Syndrome Drug, Established Date
  9. 3.9 Global Basal Cell Nevus Syndrome Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Transgene SA
  2. 4.1.1 Transgene SA Company Information
  3. 4.1.2 Transgene SA Business Overview
  4. 4.1.3 Transgene SA Basal Cell Nevus Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Transgene SA Basal Cell Nevus Syndrome Drug Product Portfolio
  6. 4.1.5 Transgene SA Recent Developments
  7. 4.2 PellePharm Inc
  8. 4.2.1 PellePharm Inc Company Information
  9. 4.2.2 PellePharm Inc Business Overview
  10. 4.2.3 PellePharm Inc Basal Cell Nevus Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 PellePharm Inc Basal Cell Nevus Syndrome Drug Product Portfolio
  12. 4.2.5 PellePharm Inc Recent Developments
  13. 4.3 Mayne Pharma Group Ltd
  14. 4.3.1 Mayne Pharma Group Ltd Company Information
  15. 4.3.2 Mayne Pharma Group Ltd Business Overview
  16. 4.3.3 Mayne Pharma Group Ltd Basal Cell Nevus Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Mayne Pharma Group Ltd Basal Cell Nevus Syndrome Drug Product Portfolio
  18. 4.3.5 Mayne Pharma Group Ltd Recent Developments
  19. 4.4 Galderma SA
  20. 4.4.1 Galderma SA Company Information
  21. 4.4.2 Galderma SA Business Overview
  22. 4.4.3 Galderma SA Basal Cell Nevus Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Galderma SA Basal Cell Nevus Syndrome Drug Product Portfolio
  24. 4.4.5 Galderma SA Recent Developments
  25. 4.5 Adgero Biopharmaceuticals Holdings Inc
  26. 4.5.1 Adgero Biopharmaceuticals Holdings Inc Company Information
  27. 4.5.2 Adgero Biopharmaceuticals Holdings Inc Business Overview
  28. 4.5.3 Adgero Biopharmaceuticals Holdings Inc Basal Cell Nevus Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Adgero Biopharmaceuticals Holdings Inc Basal Cell Nevus Syndrome Drug Product Portfolio
  30. 4.5.5 Adgero Biopharmaceuticals Holdings Inc Recent Developments
5 Global Basal Cell Nevus Syndrome Drug Market Scenario by Region
  1. 5.1 Global Basal Cell Nevus Syndrome Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Basal Cell Nevus Syndrome Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Basal Cell Nevus Syndrome Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Basal Cell Nevus Syndrome Drug Sales by Region: 2027-2032
  5. 5.3 Global Basal Cell Nevus Syndrome Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Basal Cell Nevus Syndrome Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Basal Cell Nevus Syndrome Drug Revenue by Region: 2027-2032
  8. 5.4 North America Basal Cell Nevus Syndrome Drug Market Facts & Figures by Country
  9. 5.4.1 North America Basal Cell Nevus Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Basal Cell Nevus Syndrome Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Basal Cell Nevus Syndrome Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Basal Cell Nevus Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Basal Cell Nevus Syndrome Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Basal Cell Nevus Syndrome Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Basal Cell Nevus Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Basal Cell Nevus Syndrome Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Basal Cell Nevus Syndrome Drug Market Facts & Figures by Country
  35. 5.7.1 South America Basal Cell Nevus Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Basal Cell Nevus Syndrome Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Basal Cell Nevus Syndrome Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Basal Cell Nevus Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Basal Cell Nevus Syndrome Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Basal Cell Nevus Syndrome Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Basal Cell Nevus Syndrome Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Basal Cell Nevus Syndrome Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Basal Cell Nevus Syndrome Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Basal Cell Nevus Syndrome Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Basal Cell Nevus Syndrome Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Basal Cell Nevus Syndrome Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Basal Cell Nevus Syndrome Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Basal Cell Nevus Syndrome Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Basal Cell Nevus Syndrome Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Basal Cell Nevus Syndrome Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Basal Cell Nevus Syndrome Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Basal Cell Nevus Syndrome Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Basal Cell Nevus Syndrome Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Basal Cell Nevus Syndrome Drug Value Chain Analysis
  2. 8.1.1 Basal Cell Nevus Syndrome Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Basal Cell Nevus Syndrome Drug Production Mode & Process
  5. 8.2 Basal Cell Nevus Syndrome Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Basal Cell Nevus Syndrome Drug Distributors
  8. 8.2.3 Basal Cell Nevus Syndrome Drug Customers
9 Global Basal Cell Nevus Syndrome Drug Analyzing Market Dynamics
  1. 9.1 Basal Cell Nevus Syndrome Drug Industry Trends
  2. 9.2 Basal Cell Nevus Syndrome Drug Industry Drivers
  3. 9.3 Basal Cell Nevus Syndrome Drug Industry Opportunities and Challenges
  4. 9.4 Basal Cell Nevus Syndrome Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst